June 23, 2021 5:39pm

Pre-open indications: 4 HITs and 1 MISS

The Biostage (BSTG) Chronicles: the annual meeting on Thursday 6/24/21, will there be any answers? … https://www.regmedinvestors.com/articles/11968

My comments try to distinguish the temporary from real pricing digression or progress.

If you’re looking for sector intel, ideas and facts or numbers (which don’t lie) in a volatile climate, RMi defines the rigors of share pricing! My comments distinguish the temporary from real pricing digression or progress.

Subscription is coming in July, it’s not conscription but, an offer to join our collective of like-minded investors!  


The Dow closed DOWN -71.34 points (-0.21%); the S&P closed DOWN -4.60 points (-0.11%) while the Nasdaq closed UP +18.47 points (+0.13%)

 

Henry’omics:

Indexes strayed (the S&P and Down flopped) as the market’s rally hit the wall.

  • In June, the Nasdaq has risen +3.8%m the S&P +1.8% as the Dow slipped into the red.

 

RegMed Investors’ (RMi) pre-open: “a cautious outlook as the cell and gene therapy sector struggles for direction.” …  https://www.regmedinvestors.com/articles/11967

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines:

  • Wednesday opened positive at 24/10 and 1 acquired, stayed positive at the mid-day to 17/15, and 1 acquired, closing positive at 25/9 and 1 acquired;

 

The Biostage (BSTG) Chronicles: The “pump” is STILL TRYING to promote on Wednesday as the share price popped and dropped -$0.05 to $1.25 with 11,915 shares traded after Tuesday with the share price INFLATED +$0.09 with 4,779 shares trading, Monday closed flat at $1.21 with 572 shares traded following Friday closing flat at $1.21 with 333 shares traded, Thursday’s volume of 735 shares dropping the price -$0.09 to $1.21 and last Wednesday 200 shares drove the price +$0.089 to $1.30 … WHO is buying this “zombie” as IF we didn’t know? BSTG NEEDS to “pump” the share price for the annual meeting on Thursday!

 

Pre-open Indications: 4 HITs <Biostage (BSTG -$0.05), Editas Medicine (EDIT +$1.41), Intellia Therapeutics (NTLA +$4.68), Verastem (VSTM -$0.02)> and 1 MISS < Cellectis SA (CLLS +$0.19)>  

 

RegMed/Cell and Gene Therapy Earnings Scorecard Q1/21 LPS Results: https://www.regmedinvestors.com/articles/11628

 

There are clear winners and losers

Jumping with share pricing momentum:

  • Intellia therapeutics (NTLA), Vericel (VCEL), Fate Therapeutics (FATE), Alnylam Pharmaceuticals (ALNY) - again, CRISPR Therapeutics (CRSP) to name 5 of the 25 inclining of the 35 covered

Hammered in today’s market:

  • ReNeuron (RENE.L) - again, Ultragenyx (RARE), uniQure NV (QURE) - again, MiMedx (MDXG) – again, bluebird bio (BLUE) to name 5 of the 9 declining of the 35 covered

 

Key metrics:

  • Sector volume was LOW with 4 of the 25-upside having higher than the 3-month average volume with HIGH volume of 6 of 9-downside having higher than the 3-month average volume;
  • Wednesday’s percentage (%) of the 25-upside were +0.14% (AXGN) to +6.11% (VCEL) while the 9-downside ranges from -0.47% (VSTM) to -3.85% (BSTG);

 

Wednesday’s (10 of 25) incliners:

  • Intellia therapeutics (NTLA +$4.68);
  • Vericel (VCEL +$3.73);
  • Fate Therapeutics (FATE +$2.11 after Tuesday’s -$0.48 and Monday’s +$1.67);
  • Alnylam Pharmaceuticals (ALNY +$1.68 after Tuesday’s +$1.69 and Monday’s -$5.63);
  • CRISPR Therapeutics (CRSP +$1.48);
  • Editas Medicine (EDIT +$1.41 after Tuesday’s -$0.45 and Monday’s +$0.98);
  • Sage Therapeutics (SAGE +$0.69 after Tuesday’s -$1.75 and Monday’s +$0.56);
  • Regenxbio (RGNX +$0.390;
  • Precigen (PGEN +$0.30 after Tuesday’s +$0.03 and Monday’s -$0.08);
  • Chinook Therapeutics (KDNY +$0.22 after Tuesday’s -$1.04 and Monday’s +$0.34);

Wednesday’s (9 of 9) decliners:

  • ReNeuron (RENE.L -$2.50 after Tuesday’s -$5.55);
  • Ultragenyx (RARE -$1.05 after Tuesday’s -$0.72 and Monday’s +$0.57);
  • uniQure NV (QURE -$0.56 after Tuesday’s -$2.31 with news);
  • MiMedx (MDXG -$0.43 after Tuesday’s -$1.00);
  • blue bird bio (BLUE -$0.41);
  • Global Blood Therapeutics GBT -$0.34 after Tuesday’s -$0.67);
  • Mesoblast (MESO -$0.20 after Tuesday’s +$0.12);
  • Biostage (BSTG -$0.05 after Tuesday’s+$0.09);
  • Verastem VSTM -$0.02 after Tuesday’s -$0.57);

Closing 1 -Stemline Therapeutics (STML – acquired)

 

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Wednesday, the IBB closed down -0.25% and XBI closed up +0.47%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Wednesday was down -0.34 points or -2.04% at 16.32

Upside volume: weak

  • Wednesday: 4 out of the 25-upside had higher than the 3-month average volume;

Downside volume:

  • Wednesday: 6 out of the 9-downside had higher than the 3-month average volume;

Percentage (%) movement/range statistics: price versus percentage …

  • Wednesday’s percentage (%) of the 25-upside were +0.14% (AXGN) to +6.11% (VCEL) while the 9-downside ranges from -0.47% (VSTM) to -3.85% (BSTG);

June, third month of Q2/21:

Wednesday positive with 25 advancers, 9 decliners and 1 acquired

 

The BOTTOM LINE: the sector is up but, still struggling for direction – look at the volume and percentages (%) in the stats - weak.

As I stated this a.m. – a cautious outlook … don’t get complacent … WHO has presented clinical data: uniQure NV (QURE) the stock went down, Thursday Applied genetic technologies (AGTC) will present 12-month data for adult patients and low dose pediatric patients in its Phase 1/2 clinical Achromatopsia (ACHM) trials – it is UP +$0.61 or +14.87% in the aftermarket after closing up only +$0.03 to $4.17. While Editas medicine (EDIT) announced an enrollment in a pediatric trial which did see movement +$1.41 or +3.87% which I believe will be sold into on Thursday.

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.